Low Dose Ruxolitinib in Combination With Methylprednisolone
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is to determine the efficacy and safety of combined Low dose Ruxolitinib With
Methylprednisone as Initial Therapy for the aGVHD(acute graft-versus-host disease )